Vaxart, Inc. 8-K

What Happened
Vaxart, Inc. announced on July 6, 2026 (filed via Form 8‑K on July 7, 2026) topline 12‑month safety results from the approximately 400‑participant sentinel safety cohort of its Phase 2b trial comparing its oral pill COVID‑19 vaccine candidate to an approved mRNA vaccine comparator. The company reported that no vaccine‑related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events were observed in either study arm. The announcement is presented in a press release attached to the Form 8‑K as Exhibit 99.1.

Key Details

• Study cohort: ~400 participants in the Phase 2b sentinel safety cohort.
• Follow‑up period: 12 months of safety data reported.
• Safety outcome: No vaccine‑related SAEs and no sustained Grade 3+ adverse events reported in either the Vaxart oral vaccine arm or the approved mRNA comparator arm.
• Filing/announcement: Press release dated July 6, 2026; Form 8‑K filed July 7, 2026 (Exhibit 99.1).

Why It Matters
This safety update provides investors with an important data point on the tolerability of Vaxart’s oral COVID‑19 vaccine through one year in an initial sentinel cohort, and confirms no major safety signals versus an approved mRNA vaccine in this group. While this is a safety topline from a sentinel cohort (not full efficacy or larger population results), the absence of reported vaccine‑related SAEs or sustained severe adverse events is a favorable outcome for the program’s clinical risk profile. The press release is the primary source for these topline results; investors should watch for full data releases and additional trial updates for efficacy, larger safety populations, and regulatory context.